Search for Clinical Trial Results

Sponsored By

Multiple Endocrine Neoplasia - 16 Studies Found

Status Study
Active, not recruiting Study Name: Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Condition: Multiple Endocrine Neoplasia
Date: 2007-07-12
Interventions: Behavioral: Questionnaire Mailed packets including cover letter describing purpose of study, study quest
Completed Study Name: Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
Condition: Multiple Endocrine Neoplasia Syndromes
Date: 2017-02-07
Interventions: Behavioral: Questionnaires Multiple Endocrine Neoplasia Sy
Completed Study Name: Vancomycin Associated Red Man Syndrome (RMS)
Condition: Red Man Syndrome
Date: 2009-01-14
Completed Study Name: Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
Condition: Multiple Endocrine Neoplasia
Date: 2017-02-07
Completed Study Name: Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Condition:
  • Multiple Endocrine Neoplasia
  • Pancreatic Neuroendocrine Tumors Date: 2017-02-13
    Interventions:
    • Other: Genome Sequencing Analy
Completed Study Name: Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Condition:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    Date: 2011-08-26
Active, not recruiting Study Name: Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Condition:
  • Medullary Thyroid Carcinoma
  • Multiple Endocrine Neoplasia Type 2
    Date: 2007-08-08
    Interventions: Drug: Vandetanib once daily continuously (28 day cycles)
Not yet recruiting Study Name: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Condition: Pancreatic Neuroendocrine Tumors in MEN1
Date: 2016-03-02
Interventions: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied.
Completed Study Name: High Dose Somatostatin Analogues in Neuroendocrine Tumors
Condition:
  • Respiratory Tract Neoplasms
  • Thymic Neoplasms
  • Pancreatic Ne
    Date: 2009-10-05
    Interventions: Drug: Octreotide-LAR Octreotide-LAR 30 mg administered every 21 days until progression
Terminated Study Name: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Condition:
  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Adrenal Gland Tumor
    Date: 2009-07-23
    Interventions:
    • Drug: pertuzumab 840 mg, 420 m
Next >>>